Featured

Status

Health Topics

Any Category
Diseases
Immune System Diseases
Clear Filters

Search Clinical Trials

59 Results
Recruiting
Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas
Earlier, healthy donors gave blood for us to make CD30.CAR-EBVST cells in the laboratory. These cells were grown and frozen and the investigators will select the donor which the investigators …
Baylor Role: Lead Sponsor
Recruiting
CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)
Earlier, a healthy donor provided blood to make ANCHOR cells in the laboratory. These cells were grown and frozen for later use. To make the ANCHOR cells, the investigators took …
Baylor Role: Lead Sponsor
Recruiting
Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen
To make the T cells the investigators will take blood from the patient or from the previous bone marrow transplant donor and stimulate it with growth factors to make the …
Baylor Role: Lead Sponsor
Recruiting
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
To prepare the CD30.CAR T cells, research staff will take some blood from the subject. This would be drawn as two separate blood collections. Alternatively, if the subject's blood counts …
Baylor Role: Lead Sponsor
Terminated
Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis
Tuberous sclerosis complex (TSC) is an autosomal dominant disorder caused by mutations in tuberous sclerosis complex 1 (TSC1) or TSC2 tumor suppressor genes. TSC is characterized by tumors in a …
Baylor Role: Lead Sponsor
Completed
Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)
The investigators will draw blood from the subject to make EBV-specific cytotoxic T-lymphocytes (EBVSTs) in the lab. Investigators will make the cells by first growing a special type of cells …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Administration of Donor MultiTAA-Specific T Cells for ALL
To make donor-derived multiTAA-specific T cells, the investigators will collect blood from the patient's stem cell donor, and mix the donor's T cells with small pieces of the tumor proteins …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
Treatment will consist of 4 main phases: Remission Induction, Consolidation, Reinduction, and Maintenance. High risk patients will receive a reintensification phase prior to transplant in first remission. REMISSION INDUCTION: Chemotherapy …
Baylor Role: Collaborator
Recruiting
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
Up to 390 mL (78 teaspoons) of blood will be collected from the patient on one to three occasions over a two month period. Under certain conditions related to the …
Baylor Role: Lead Sponsor
Recruiting
Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)
A healthy donor has given blood to make LMP/BARF1/EBNA-1 MABEL CTLs in the lab. We made the cells by first growing a special type of cells called activated T cells …
Baylor Role: Lead Sponsor